Trinity Biotech (TRIB) Cash from Financing Activities (2017 - 2024)

Trinity Biotech has reported Cash from Financing Activities for 6 years, with the latest figure at $1.8 million in Q4 2024.

• Quarterly Cash from Financing Activities rose 202.21% year-over-year to $1.8 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$4.2 million (up 49.64% YoY) and the FY2025 annual result came in at $12.1 million, down 58.17% from the prior year.
• Cash from Financing Activities improved to $1.8 million in Q4 2024 per TRIB's latest filing, from -$1.8 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $1.8 million in Q4 2024 and troughed at -$3.6 million in Q4 2021.
• A 4-year average of -$1.3 million and a median of -$1.8 million in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities soared 257.86% in 2022, then retreated 2.49% in 2023.
• Over 4 years, Cash from Financing Activities stood at -$3.6 million in 2021, then surged by 48.56% to -$1.8 million in 2022, then rose by 4.28% to -$1.8 million in 2023, then jumped by 202.21% to $1.8 million in 2024.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $1.8 million, -$1.8 million, and -$2.4 million for Q4 2024, Q4 2023, and Q3 2023 respectively.